Riddhi Siddhi Gluco Biols FY26 profit falls 40%

Key takeaway for investors

Riddhi Siddhi Gluco Biols Limited has reported a weaker profitability profile in its audited numbers for the year ended March 31, 2026. Standalone profit fell sharply even as total income increased, indicating pressure below the topline. On a consolidated basis, the company reported a loss, with the announcement attributing the outcome to an impairment hit linked to discontinued operations. The latest quarterly disclosures referenced in the same set of information also show that profitability remained under stress through Q3 FY26.

FY26 audited results: standalone profit down, income up

For FY26, the company reported a standalone net profit of ₹56.31 crore, down from ₹94.12 crore in the previous year. Over the same period, total income rose to ₹302.64 crore, while expenses increased to ₹236.19 crore. The combination suggests that higher costs and other below-the-line movements outweighed the benefit of higher income. The year-on-year decline in profit is material in absolute terms given the previous year’s reported base.

The FY26 audited announcement also provided a consolidated snapshot that differed sharply from the standalone picture. On a consolidated basis, Riddhi Siddhi Gluco Biols posted a net loss of ₹12.23 crore. The loss was stated to be impacted by an impairment loss of ₹27.84 crore tied to discontinued operations, a factor that can distort year-on-year comparability when presented alongside continuing business results.

Consolidated performance: impairment and discontinued operations in focus

The disclosure explicitly connects consolidated weakness to discontinued operations, via an impairment charge. In practical terms, this means the consolidated result is not only a reflection of current-period trading performance but also an accounting adjustment linked to assets or operations that are no longer part of the active business. As a result, investors typically separate the discussion into continuing operations versus discontinued operations when assessing the underlying earnings trend.

In the same information set, the company’s quarterly commentary also flags that discontinued paper division operations were a drag on consolidated numbers. That context is important because it aligns with the impairment explanation in the audited full-year release. But it also means consolidated profitability may remain volatile until legacy issues are fully resolved and disclosures stabilise.

Q3 FY26 snapshot: profit drop on standalone basis

Riddhi Siddhi Gluco Biols’ Q3 FY26 standalone performance, as stated, showed a steep year-on-year decline in net profit. Standalone net profit for Q3 FY26 came in at ₹8.86 crore, down 66.73% from ₹26.63 crore a year ago. Revenue was described as relatively stable at ₹31.24 crore.

On the consolidated side for Q3 FY26, the company posted a net loss of ₹1.29 crore, with the loss attributed to discontinued paper division operations in the same source. It also stated that continuing operations generated a profit of ₹0.39 crore, suggesting that the active portion of the business remained marginally profitable while discontinued operations pulled the consolidated result into the red.

Another Q3 FY26 view: operating loss and margin pressure

The provided material also includes an additional Q3 FY26 performance description that highlights deeper operational stress. It cites a consolidated net loss of ₹1.59 crore for Q3 FY26, contrasting it with a profit in the previous quarter, and notes negative operating margins. It also reports that operating profit before depreciation, interest, tax, and other income (PBDIT excluding other income) fell to a loss of ₹5.53 crore in Q3 FY26 versus a profit of ₹1.55 crore in Q2 FY26, translating to an operating margin of -13.80%.

The same source reports profit before tax less other income at -₹10.12 crore for Q3 FY26. Taken together, these figures point to a quarter where operating performance weakened meaningfully, and where non-operating items can significantly change the reported bottom line.

Stock and price levels mentioned in the data

The information set provides multiple market-price references across dates. One reference states the stock traded at ₹530.00 as of February 06, 2026, which was 23.30% below a 52-week high of ₹691.00 and 30.86% above a 52-week low of ₹405.00. Another data point mentions the stock last traded at ₹514.45, down 0.30% from a previous close of ₹516.00. A separate reference states that the stock was at ₹534.00 as of November 14, 2025, down 1.30% in that session.

These datapoints do not explain the drivers of the moves, but they frame the period as one where the stock traded well below its 52-week peak.

Cost structure signals from FY25

Beyond FY26 and Q3 FY26, the provided content also includes cost structure indicators for the year ended March 31, 2025. It states the company spent 7.2% of operating revenues on interest expenses and 6.05% on employee cost in FY25. It also references FY25 standalone March 2025 net sales at ₹16.69 crore, down 55.71% year-on-year.

While these are from an earlier period, they add context to the broader profitability debate because interest costs and operating leverage can amplify earnings swings when revenues are volatile.

Summary table of key reported figures

Why the FY26 print matters

The audited FY26 numbers show a divergence between income growth and profit outcomes on a standalone basis, and a further deterioration when viewed on a consolidated basis. The impairment linked to discontinued operations is a key explanatory item for the consolidated loss and changes how investors interpret the reported bottom line. Meanwhile, the Q3 FY26 operating loss and negative margin cited in the data underscore that the near-term earnings trajectory has been challenged even before the year-end print.

What to watch next

Investors will likely track whether discontinued operations continue to create large non-recurring impacts and how management commentary frames the remaining business performance. The next set of quarterly disclosures should help clarify whether operating margins normalise from the weak levels cited for Q3 FY26. Any further detail around impairment, discontinued assets, and segment profitability will be central to understanding the quality and sustainability of earnings.